Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
g! R, ~3 f5 M3 c9 M* g" l7 ]7 K7 K+ b: ~
- K( r* l3 n J, p8 e KSub-category:
]6 U# G6 i3 J. ^7 \+ ?Molecular Targets
/ m! M1 i% ?6 @, H" h2 T. _4 \+ z+ K7 p6 E
% C3 P' N- }* E! \+ WCategory:
1 Y8 e9 X, \# ^Tumor Biology
! B+ o* }; Y1 Q4 O3 s' K2 o$ T
H2 H- k2 t% e0 E# l @. A; U. o1 M8 S* U* A3 x+ \
Meeting:2 p; Z# X; Q' b: X ~3 B9 h
2011 ASCO Annual Meeting
7 S. Z' j: m5 n2 d* j' h" ~* y; L+ l6 a5 L
# ]: C7 k& t' S* j" ~# \! ~
Session Type and Session Title:$ l# ]$ ^3 G5 o. K3 K: u
Poster Discussion Session, Tumor Biology o$ ~0 U3 g. O! K
' }! d, y& H, O" v! m3 A* `) A: ]
: v7 F5 p3 ^# \Abstract No:
& `$ D$ ~( X( N( M) `5 O10517
( v; Q& C4 v- }$ a- N& {# b3 E& B5 c; F
* v& O- v4 {8 V+ b7 T, R& F4 i! E* z- E
Citation:# f6 }: x2 K* o! `! n
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ N. N6 ?. F6 S D
; g6 K2 |' |) L6 f( `+ I+ E
1 h0 W2 Z( ^ a6 N8 g0 QAuthor(s):: S/ ? p2 A1 \4 [5 I" B9 x
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
; U7 ]) j; K2 I6 g, n f% R& O8 |0 Q5 M$ G! i ~! U+ Y- [. |2 i$ Z
/ X, V7 J3 H8 p, z
# A# ^ q0 z9 i3 }! [Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings./ p3 v; N, p( Z! g3 M
& b* k# c. @* L5 ]3 MAbstract Disclosures8 R4 F$ h: {4 K( `9 T! e8 `: D
' ^: u, x7 h5 J9 k
Abstract:
4 ?0 i/ a) c# ~% j# }: s2 O
# X. T5 N5 V' n2 W/ f5 d% Z3 l9 @& E4 k* F. Y& ^: U/ w2 Y2 B% Q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.* W" ?. X% g: _0 E' B1 ~" H9 a4 x# M
2 p5 |2 E, [# A) u5 y) }- @
; l z! w3 L' v3 u+ p- Q |
显身卡
